ライフサイエンスコーパス: remission rate

1 motherapy for AML resulted in an encouraging remission rate.

2 inition all were associated with the placebo remission rate.

3 ion despite new therapies that have improved remission rates.

4 DR group but were not related to symptomatic remission rates.

5 e, the groups did not differ in response and remission rates.

6 cebo, but with no significant improvement in remission rates.

7 idence of an effect on [corrected] long-term remission rates.

8 ity of life were associated with lower HAM-D remission rates.

9 nonsignificant improvements in response and remission rates.

10 y at entry have a large influence on placebo remission rates.

11 were similar to those affecting the placebo remission rates.

12 factor scores of HDRS-17s, or in response or remission rates.

13 se they do not increase clinical response or remission rates.

14 litis and bilateral optic neuritis have poor remission rates.

15 ever, predisposes to significantly lower T2D remission rates.

16 ations, significantly diminished overall T2D remission rates 14 months after RYGB surgery (9%) compar

17 The diabetes remission rate 2 years after surgery was 16.4% (95% CI,

18 , however, increased significantly T2D early remission rates (22%), compared with patients not taking

19 72.7% and 61.5% vs. 33.3%, respectively) and remission rates (27.3% and 38.5% vs. 16.7%, respectively

20 rol difference in response rates (24.1%) and remission rates (30.1%), with adult differences generall

21 82%), response rates (79.3% and 73.3%), and remission rates (34.5% and 24.4%) at the posttreatment a

22 ts were also seen in the patient-rated MADRS remission rate (36.0% vs 22.0%; nominal P = .03) and res

23 priori categorizations defined response and remission rates: 54.4% of olanzapine-treated patients re

24 19.6 x 10(9)/L; P =.005) and lower complete remission rate (55% versus 76%; P =.046) than mutation-n

25 Diabetes remission rates 6 years after surgery were 62% (95% CI,

26 w minimal residual disease-negative complete remission rate (64% vs 43%, P = .016).

27 ite light experienced a significantly higher remission rate (68.2% compared with 22.2%; adjusted odds

28 a significantly higher overall and complete remission rate (72% vs 51%, P = .003; 7% vs 0%, P = .011

29 There was no overall difference in complete remission rate (73% vs 75%; odds ratio, 1.07 [0.83-1.39]

30 abeled BC8 therapy yielded improved complete remission rates (75% vs 0%, P < .001) and progression-fr

31 ates (90% v 87%), achieved a higher complete remission rate (78% v 65%; P = .025).

32 rapy compared with wild-type cases (complete remission rate, 79% v 90%, odds ratio [OR] = 3.02; 95% C

33 Complete remission rates (89%) did not differ but were attained f

34 Higher complete remission rates (91%) were achieved in children with DS

35 of children, respectively, with the highest remission rates achieved with calcineurin inhibitor-base

36 r commissure plane was associated with a low remission rate after age was considered.

37 on induction treatment, with a high complete remission rate after course 1 and reduced relapse.

38 Because the remission rate after treatment is similar among patients

39 productivity is associated with much higher remission rates after 3 and 7 months of treatment.

40 The PTCLs are characterized by high remission rates after frontline therapy, but relapse ine

41 Complete remission rates after induction tended to be lower in VP

42 nic lymphocytic leukemia (CLL) exhibits high remission rates after initial chemoimmunotherapy, but wi

43 Despite high remission rates after therapy, 60% to 70% of patients wi

44 depression remitted compared with only a 12% remission rate among children of mothers whose depressio

45 o-treat remission rates nor the response and remission rates among study completers differed signific

46 of the first randomisation was the complete remission rate, analysed by modified intention to treat.

47 This study sought to determine the remission rate and identify predictors of persistence an

48 side, and cyclophosphamide results in a high remission rate and may provide long-term disease-free su

49 We studied the influence of comorbidities on remission rate and overall survival (OS) in patients wit

50 acute myeloid leukemia (AML) may improve the remission rate and reduce the risk of relapse, thereby i

51 No apparent relations between the remission rate and sex or the use of steroids was detect

52 ning induction regimen improved the complete-remission rate and whether maintenance therapy with ritu

53 re prespecified as an odds ratio of 0.49 for remission rates and a Cohen's d value of 0.30 for contin

54 phoblastic leukemia (ALL) is hampered by low remission rates and high toxicity, especially in second

55 osure was associated with decreased complete remission rates and inferior survival (3-year adjusted R

56 myeloid leukemia (AML), IDA achieves higher remission rates and longer remission durations.

57 The surgery group had higher remission rates and lower incidence rates of hypertensio

58 eral chemotherapy schedules achieved similar remission rates and OS.

59 ears of age remains unsatisfactory, with low remission rates and poor overall survival.

60 cules might well be able to further increase remission rates and potentially also cure rates.

61 pared with high-education patients; however, remission rates and survival were not affected in those

62 id leukemia (AML) have been shown to improve remission rates and survival.

63 s gasseri-dominated CSTs had the fastest HPV remission rate, and a low Lactobacillus community with h

64 a as younger patients, toxicity, hematologic remission rate, and survival were not significantly diff

65 Secondary outcome was remission rate, and tertiary outcomes were changes in Re

66 score from baseline to week 12, response and remission rates, and changes in Clinical Global Impressi

67 e trial, depression scale used, response and remission rates, and discontinuation rates for any reaso

68 NA expression associates with lower complete remission rates, and shorter event-free and overall surv

69 f acute myeloid leukemia (AML) achieves high remission rates, approximately 75-80% of patients will e

70 In Crohn disease similar remission rates are achieved with enteral nutrition as w

71 The placebo remission rates are influenced by the trial length, numb

72 High complete remission rates are typically achieved, but relapse rema

73 n approach and modeled sex- and age-specific remission rates as a function of incidence and prevalenc

74 Remission rates as assessed by the HRSD-17 and the QIDS-

75 Colchicine also improved the remission rate at 1 week (85.0% vs. 58.3%, P<0.001).

76 at baseline was associated with a decreased remission rate at month 6 (odds ratio, 0.16; 95% confide

77 Patients unimproved at week 6 had a remission rate at week 12 of 31%-41%.

78 Remission rates at 1 year in patients continuing MEN wer

79 iglyceridemia was the only comorbidity whose remission rates at 1 year of follow-up (partial/complete

80 Primary end points were sustained remission rates at 12 months and severe adverse events.

81 Remission rates at 12 weeks were 22.3% (n = 114) for the

82 with robust improvement had 3-5 times higher remission rates at 3 months and 2-5 times higher remissi

83 ric populations), and estimated response and remission rates at 6 weeks were analyzed for 2635 adults

84 ssion rates at 3 months and 2-5 times higher remission rates at 7 months, even after controlling for

85 Remission rates at 9 months were lower in patients treat

86 IL2DT was associated with improved complete remission rates at day 28 (53% vs 21%; P = .02) and dise

87 Remission rates at week 12 were significantly greater in

88 47.1% and 29.3%; at week 12:56.7% and 34.0%; remission rates at week 9: 37.9% and 21.7%; at week 12:

89 eated patients also had significantly higher remission rates at Weeks 4, 8, and 12 (P < or = .009).

90 CBT-SAD and light therapy did not differ in remission rates based on the SIGH-SAD (47.6% and 47.2%,

91 Remission rates, based on the Crohn's Disease Endoscopic

92 During the observational phase, remission rates before change of assigned treatment were

93 There was no difference in remission rates between groups, with similar numbers fla

94 Differences in remission rates between the group given 3 mg of anti-int

95 ity of anxiety at baseline predicted a lower remission rate but did not moderate aripiprazole efficac

96 d patients did not differ regarding complete remission rate, but had shorter disease-free survival (D

97 , FLT3 inhibition was highly correlated with remission rate, but target inhibition on day 15 was achi

98 Added treatment generally improves remission rates, but approximately one third of all pati

99 dose intensification in the case of relapse, remission rates, but not response rates, at week 54 were

100 At 12 months, response and remission rates (CALM vs UC) were 63.66% (95% CI, 58.95%

101 Knowledge about remission rates can affect treatment decisions and facil

102 Corresponding remission rates (CGI = 1) were 2 of 27 (7.4%), 3 of 34 (

103 mesial temporal lobe epilepsy offers seizure remission rates comparable with those reported previousl

104 non-CBF aberrant karyotypes and led to lower remission rates (complete remission + complete remission

105 The complete remission rate /complete remission with incomplete plate

106 ), relapse-free survival (RFS), and complete remission rates (CR) were not influenced by the presence

107 After 6 cycles, the complete remission rate (CRR) was 64%, and 36% were MRD negative.

108 pared with 40.9%) and a significantly higher remission rate (cumulative first-time remitters, 43.3% c

109 At 15 years, the diabetes remission rates decreased to 6.5% (4/62) for control pat

110 The remission rate, defined as a final Hamilton depression s

111 The aims were to determine remission rate, depression symptom level, and rate of mo

112 ical treatment (73.9% versus 35.0%), but the remission rate did not differ between the groups (34.8%

113 However, clinical response and remission rates did not differ significantly between pat

114 Remission rates did not differ significantly either as a

115 Last observation carried forward remission rates did not significantly differ between tre

116 he differences narrowed at 6 months, but the remission rates differed again at 9 months (73%, 57%, an

117 zapine/sertraline was associated with higher remission rates during the trial than olanzapine/placebo

118 re treatment steps are required, lower acute remission rates (especially in the third and fourth trea

119 CTL019 was associated with a high remission rate, even among patients for whom stem-cell t

120 Specifically, long-term remission rates following bariatric surgery are largely

121 The complete remission rate for all 155 patients was 82%, compared wi

122 ata may allow useful modeling of an expected remission rate for any population of patients who experi

123 The clinical and endoscopic remission rate for ASACOL (32.6%; P = .124) was not sign

124 e for second and subsequent relapse, but our remission rate for early first relapse seems better than

125 t minimal residual disease-negative (MRD(-)) remission rate for this phase 1 study was 89%.

126 Remission rate for type 2 diabetes was 87.5% (21/24) and

127 The week 12 remission rate for unimproved patients at week 4 was cle

128 gnificant reductions in these comorbidities; remission rates for all comorbidities were higher after

129 Although remission rates for metastatic melanoma are generally ve

130 Response and remission rates for natalizumab were superior to those f

131 The complete remission rates for patients with early favorable, early

132 Remission rates for patients with RAEB in transformation

133 RIs) are associated with better response and remission rates for postnatal depression.

134 7 v 40.7 months, respectively; P = .05), and remission rate (>/= very good partial remission; 23% v 4

135 Secondary outcome measures included partial remission rates (>85% of expected weight for height plus

136 he primary outcome measure was posttreatment remission rate (HAM-D score </=7).

137 se with higher expression had lower complete remission rates, higher primary refractory rates, and sh

138 issue of Blood, Ostronoff et al report a low remission rate in acute myeloid leukemia (AML) patients

139 in the placebo group (50% [95% CI, 36%-64%] remission rate in both groups).

140 Because of the low remission rate in Graves' disease and the inability to c

141 rly synergize with Lipo ATRA to increase the remission rate in immunocompetent mice.

142 The complete remission rate in patients with unfavorable cytogenetics

143 Complete remission rate in the DAC arm was higher compared with t

144 In spite of high complete remission rates in Acute Myeloid Leukemia (AML), little

145 tions that fail to improve baseline complete remission rates in comparable populations are unlikely t

146 k between eosinophil levels and severity and remission rates in IBD has led to speculation that eosin

147 ariatric surgery determines similar diabetes remission rates in patients with BMI of 35 kg/m2 or more

148 Follow-up studies of BED are scarce; remission rates in randomized controlled trials ranged f

149 The complete remission rates in the 2 arms were not different (65%).

150 Remission rates in the CBT, psychodynamic therapy, and w

151 very rates were related to higher functional remission rates in the DR group but were not related to

152 Infliximab-treated patients showed similar remission rates in the MTX and other DMARD cotherapy gro

153 nomodulatory drugs (IMiDs) that produce high remission rates in the treatment of multiple myeloma.

154 The response and remission rates in this highly generalizable sample with

155 Remission rates included FBT, 33.1% at the EOT and 40.7%

156 e older and had significantly lower complete remission rates, inferior event-free, relapse-free, and

157 The remission rate is believed to be low, and it is still ob

158 ype 2 diabetes mellitus (T2DM); however, the remission rate is not the same among different surgical

159 anti-TNF therapy has strongly increased JIA remission rates, it is not curative and up to 80% of pat

160 ATRA in induction results in a high complete remission rate, leads to rapid resolution of the charact

161 gh current therapies result in high complete remission rates, long-term disease-free survival rates h

162 vels of education or income had higher HAM-D remission rates; longer index episodes, more concurrent

163 essful antidepressant trials resulted in low remission rates (<20%) among patients with major depress

164 In the pivotal study, clinical remission rates (Mayo score 0-2, with scores of 0 on rec

165 linical outcomes, including a lower complete remission rate, more frequent reinduction, and decreased

166 Despite high initial remission rates, most lymphomas relapse and require furt

167 ipramine group), neither the intent-to-treat remission rates nor the response and remission rates amo

168 (82% of NUP98/NSD1 patients) had a complete remission rate of 27% vs 69% in FLT3/ITD without NUP98/N

169 n MK(+) patients were dismal with a complete remission rate of 32.5% and a 4-year survival of 9%.

170 d with rituximab and thiotepa had a complete remission rate of 49% (95% CI 38-60), compared with 23%

171 27 individuals (67%) had a score of 0 for a remission rate of 53%.

172 xantrone and cytarabine induction achieved a remission rate of 76% for relapsed/refractory patients a

173 the 5-drug induction combination achieved a remission rate of 88%, similar to historical controls.

174 ul in 115, resulting in a long-term complete remission rate of 93.8%; 111 died of concomitant disease

175 The non-remission rate of patients who were 20-years-old or youn

176 ectomy (SG) have been associated with a high remission rate of type 2 diabetes mellitus (T2DM).

177 However, the non-remission rate of urticaria that was treated with a stan

178 lmost 100% response rate, including complete remission rates of 35% to 42%, without myelotoxicity.

179 ith complete remission and clinical complete remission rates of 73% for ABVD and 69% for Stanford V.

180 the treatment of this disease, with complete remission rates of 75% to 90% and overall survivals reac

181 Treatment with rituximab has led to remission rates of 80 to 90% among patients with refract

182 significant weight regain and a decrease in remission rates of diabetes and, to a lesser extent, oth

183 The GLP-1 agonist did not improve the remission rates of diabetic patients not taking insulin

184 prednisone showed a 2- to 4-fold increase in remission rates of GCA in a randomized clinical trial (N

185 Main Outcome Measure Remission rates of MD with psychotic features.

186 identified in 97% of evaluated patients and remission rates of medical prophylaxis in calcium stone

187 Complete remission rates of patients with mutKIT and wild-type KI

188 bypass and SG are associated with comparable remission rates of T2DM.

189 The non-remission rates of them after one week, four week and on

190 Remission rates of type 2 diabetes mellitus and metaboli

191 could not be demonstrated for posttreatment remission rates or any of the follow-up measures.

192 No differences in remission rates or increases in eGFR at 18 months were e

193 ic surgery was associated with a higher T2DM remission rate (OR: 14.1, 95% CI: 6.7-29.9, P < 0.001),

194 nt-free survival (EFS), 4-month EFS, overall remission rate (ORR; complete remission [CR] plus CR wit

195 The primary end point was overall remission rate (ORR; ie, complete remission [CR] plus CR

196 Although clofarabine doubled remission rates, overall survival was not improved overa

197 expression associated with a lower complete remission rate (P = .005) after adjustment for WBC; shor

198 e mutations associated with a lower complete remission rate (P = 0.03).

199 se, CD25(POS) patients had inferior complete remission rates (P = .0005) and overall survival (P < .0

200 RUNX1-mutated patients had lower complete remission rates (P = .005 in younger; P = .006 in older)

201 ssion independently predicted lower complete remission rates (P = .04) when adjusting for ERG express

202 The partial remission rate (PR) after two cycles of DTPACE was 32%,

203 e, potentially reducing placebo response and remission rates (reducing the risk of failed trials) but

204 Secondary outcomes included response and remission rates, relapse status after 6 months, and cogn

205 rate of improvement in symptom severity and remission rates relative to placebo during the treatment

206 However, sustained remission rates remain relatively low, and the search fo

207 Remission rates remained modest regardless of treatment

208 s for the G allele of rs28365143 had greater remission rates, response rates, and symptom reductions.

209 risk [RR], 0.90 [95% CI, 0.76 to 1.07]) and remission rates (RR, 0.98 [CI, 0.73 to 1.32]).

210 eduction in HAM-D score, higher response and remission rates, shorter time to response and remission,

211 HDRS-17, GAF, and remission rates showed no effects of EPO over saline at

212 Neither response nor remission rates statistically differed by treatment, nor

213 Endpoints were comparisons of remission rates, survival, failure-free survival (FFS),

214 rity, a greater response rate, and a greater remission rate than the supportive therapy group (respon

215 incorporating high-dose therapy yield higher remission rates than do conventional-dose treatments, bu

216 172 IDH2-mutated patients had lower complete remission rates than IDH1/IDH2wt patients (P = .007).

217 cipants had significantly greater depression remission rates than ST-CI participants (37.84% vs 13.51

218 ived two infusions of natalizumab had higher remission rates than the placebo group at multiple time

219 ies continue to focus on increasing complete remission rates that allow more transplant-eligible pati

220 next therapy, bringing the overall complete remission rate to 83%.

221 on with citalopram) had similar response and remission rates to those assigned to medication strategi

222 ensive treatment, early death rate, complete remission rate, use of allogeneic transplants, and overa

223 The authors estimated migraine remission rates using data from a 2004 national survey.

224 Spontaneous remission rates vary by report and range from 5 to 11%.

225 0% (95% CI, 63% to 76%), the nodular partial remission rate was 10%, and the partial remission rate w

226 tial remission rate was 10%, and the partial remission rate was 15%, for an overall response rate of

227 The estimated 6-month terminal seizure remission rate was 19% (95% confidence interval, 14-26%)

228 The average posttreatment remission rate was 22.7%.

229 The overall remission rate was 28%, and 2-year survival was 13%.

230 The complete remission rate was 34% (95% confidence interval [CI] 26%

231 The highest remission rate was 44 percent and the highest response r

232 The complete remission rate was 47% (n = 25), achieved after a median

233 The remission rate was 48% in the placebo/open group and 59%

234 Remission rate was 51.9% on zosuquidar and 48.9% on plac

235 The complete remission rate was 61% with 4-year disease-free survival

236 The complete remission rate was 62% for all patients with M5; 52% for

237 The overall cumulative remission rate was 67%.

238 The complete remission rate was 68% with complete remission with inco

239 Results The overall remission rate was 73% with 55% complete remissions and

240 The MRD(-) remission rate was 93% in patients who received a CAR T-

241 The complete remission rate was 96% (52 of 54 in high-risk and 127 of

242 Complete remission rate was 96% and 65% of patients achieved a 3-

243 The remission rate was directly related to extent of weight

244 of patients achieving a complete cytogenetic remission rate was superior with DAS (84% vs 69%), as wa

245 The absolute difference in clinical remission rates was 14.2 percentage points (95% CI, 6.7

246 hase 1 studies designed to improve long-term remission rates, we administered adoptive T-cell immunot

247 For mirtazapine, remission rates were 12.3% and 8.0% per the Hamilton and

248 r a mean of 9.6 weeks (SD=5.2) of treatment, remission rates were 15.9% with lithium augmentation and

249 For nortriptyline, remission rates were 19.8% and 12.4%, respectively.

250 Long-term complete and partial remission rates were 24% and 26%, respectively, whereas

251 Remission rates were 28% (HAM-D) and 33% (QIDS-SR).

252 After exclusion of these patients, the remission rates were 29.0% and 13.8% in the mesalamine a

253 in the active-stimulation group (P = .003); remission rates were 3.5% and 27.3%, respectively (P = .

254 Complete remission rates were 33.75% with FCR and 19.2% with FCCa

255 The QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for

256 pressure <140/90 mm Hg without medication), remission rates were 38.2% for gastric bypass ( n = 808)

257 Partial remission rates were 39%, 70%, and 83% after 1, 3, and 5

258 Remission rates were 4 of 27 (14.8%), 8 of 34 (23.5%), 9

259 Complete remission rates were 43% with M7 AML and 57% with non-M7

260 s were 58% in each of the active conditions; remission rates were 46% for medication, 40% for cogniti

261 er 1, 3, and 5 years, respectively; complete remission rates were 5%, 24%, and 38% at 1, 3, and 5 yea

262 Remission rates were 50.9% for venlafaxine ER and 37.5%

263 Placebo-adjusted remission rates were 56% and 45% for the initial and sub

264 % in the active-stimulation group (P = .08); remission rates were 6.7% and 13.3%, respectively (P = .

265 n <160 mg/dL, and triglycerides <200 mg/dL), remission rates were 60.4% for gastric bypass (n = 477)

266 5% without medication), sample-size-weighted remission rates were 66.7% for gastric bypass (n = 428)

267 Dyslipidemia remission rates were 93.3% (28/30) for total cholesterol

268 Moreover, the 6-year remission rates were also significantly higher for the f

269 The authors found that remission rates were an increasing function of age and w

270 Incidence and remission rates were calculated by calibrating against r

271 In the intention-to-treat sample (n = 190), remission rates were compared for the 2 treatment arms u

272 Depression remission rates were greater in the pregnenolone group (

273 Sustained-remission rates were high in both groups, and the rituxi

274 Remission rates were higher for isolated optic neuritis

275 The HAM-D response and remission rates were higher for patients treated with ad

276 t the posttreatment assessment; response and remission rates were largely maintained at the follow-up

277 Remission rates were modest for both the tranylcypromine

278 However, the absolute remission rates were modest.

279 Remission rates were nearly 40% for both treatment condi

280 Complete remission rates were not significantly different between

281 Remission rates were not significantly different between

282 ences of accelerated phase, blast crisis, or remission rates were observed between patients in the di

283 PTSD remission rates were significantly greater for the VRE-D

284 Both the response and remission rates were significantly higher in the modafin

285 The 12 month practice-level remission rates were similar at ECI and conventional man

286 Overall remission rates were similar for DA versus ADE (84% v 86

287 Remission rates were similar for the two groups (intent-

288 Although complete-remission rates were similar with R-FC and R-CHOP (40% a

289 ogs, pentostatin and cladribine, induce high remission rates when used as first-line monotherapy for

290 e/cytarabine-based approach is deployed, the remission rate will be around 50%, but the risk of subse

291 The high complete remission rate with first-line combined fludarabine, cyc

292 ion scale score >24) tended to have a higher remission rate with medication than with placebo (35% ve

293 bsorbed dose ratios and achieve high durable remission rates with diminished systemic toxicity.

294 Remission rates with FFGEDs and SFGEDs were 60% and 79%,

295 Remission rates with lithium and T(3) augmentation for p

296 Complete remission rates with or without adjuvant treatment at fi

297 ore were important predictors of the placebo remission rate, with study duration the most important.

298 imum-tolerated dosage (phase I) and complete remission rate within the first two cycles (phase II).

299 Remission rates within 12 weeks after treatment initiati

300 For these disorders, remission rates would typically be obtained from prospec